Weidong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weidong Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hua Liang
Department of Clinical Laboratory, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China
2 shared publications - Juxiang Li
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
2 shared publications - Miangliang Qiu
Department of Rheumatology, The Affiliated Hospital of Jiangxi University of Chinese Medicine, China
2 shared publications - Mo Lisha
The Affiliated Hospital of Jiangxi University of Chinese Medicine, China
2 shared publications - Weina Zhu
Department of Pediatrics, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China
2 shared publications - Xiangjuan Zheng
School of Chemistry and Chemical Engineering, Nanchang University, Nanchang 330031, China
2 shared publications
Latest Publications
- Open Access
- 29 December 2020
- Published by Peertechz Publications Private Limited in Open Journal of Orthopedics and Rheumatology
- Vol. 5 (1) , 069-072
Clinical evaluation of qingre jiedu quyu decoction in the treatment of systemic lupus erythematosus and its effect on NLRP3 inflammatory bodies
To evaluate the clinical efficacy of Qingre Jiedu Quyu Decoction in the treatment of Systemic Lupus Erythematosus (SLE) and its effect on NLRP3 inflammatory bodies.
- 29 December 2020
- Published by Peertechz Publications Private Limited in Open Journal of Orthopedics and Rheumatology
- Vol. 5 (1) , 069-072
Open AccessClinical evaluation of qingre jiedu quyu decoction in the treatment of systemic lupus erythematosus and its effect on NLRP3 inflammatory bodies
To evaluate the clinical efficacy of Qingre Jiedu Quyu Decoction in the treatment of Systemic Lupus Erythematosus (SLE) and its effect on NLRP3 inflammatory bodies.
- 16 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 967
Correction to: Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
The first name of the co-author of the above article was presented incorrect in the published version. The author name “Miangliang Qiu” should
- 16 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 967
Correction to: Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
The first name of the co-author of the above article was presented incorrect in the published version. The author name “Miangliang Qiu” should
- 26 December 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 909-917
Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
Objective miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs). Method The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3′ UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3′-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection. Results miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels. Conclusions Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA. Key Points • SOCS1 is a potential target of miR-150-5p. • miR-150-5p promoted the growth of RASF cell line MH7A. • miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.
- 26 December 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 909-917
Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
Objective miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs). Method The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3′ UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3′-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection. Results miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels. Conclusions Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA. Key Points • SOCS1 is a potential target of miR-150-5p. • miR-150-5p promoted the growth of RASF cell line MH7A. • miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.
- 1 March 2019
- Vol. 16 (2) , 170-181
Reno-Protective Effect of Realgar Nanoparticles on Lupus Nephritis of MRL/Lpr Mice through STAT1
Background: Realgar, an arsenic tetrasulfide compound, is a highly recognized traditional Chinese medicinal prescription that has been widely used to treat various diseases such as inflammatory diseases. However, there are still some problems in the clinical treatment of Realgar, such as large oral dose and high potential toxicity. Objective: To evaluate effects of Realgar nanoparticles on lupus nephritis (LN) in vivo in MRL/lpr mice. Methods: Ten-week mice were orally administered every day for eight consecutive weeks except the mice of normal model groups. The serum levels of anti-ds-DNA antibody IgG, IgM, IFN-gamma Creatinine (Cr), and blood urea nitrogen (BUN) were determined, and 24-hour urine protein was also measured. Renal inflammatory pathology analysis was assessed by hematoxylin-eosin (H&E) staining. The expression of phosphorylated signal transducer and activator of transcription 1 (p-STAT 1) and Janus Kinase 1 (JAK 1) in kidney tissue was determined by direct reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC). Results: The mice treated with Realgar nanoparticle in the high dose-treated (Realgar HD, 0.03 g/kg/d) group exhibited significantly reduced serum levels of anti-dsDNA (p<0.01), IgG (p<0.01), IgM (p<0.01), BUN (p<0.01), Cr (p<0.01), and inflammatory cytokine IFN-gamma (p<0.01) as well as proteinuria (p<0.01) compared to the untreated model MRL/lpr mice. Additionally, high doses of Realgar nanoparticles significantly suppressed the phosphorylations of STAT 1 (p<0.01) and the renal pathological changes. Conclusions: The study indicates that Realgar nanoparticles may be a potential agent to treat LN, and the down-regulated p-STAT1 expression suggests that it may be one of the LN treatment targets for Realgar nanoparticles.
- 1 March 2019
- Vol. 16 (2) , 170-181
Reno-Protective Effect of Realgar Nanoparticles on Lupus Nephritis of MRL/Lpr Mice through STAT1
Background: Realgar, an arsenic tetrasulfide compound, is a highly recognized traditional Chinese medicinal prescription that has been widely used to treat various diseases such as inflammatory diseases. However, there are still some problems in the clinical treatment of Realgar, such as large oral dose and high potential toxicity. Objective: To evaluate effects of Realgar nanoparticles on lupus nephritis (LN) in vivo in MRL/lpr mice. Methods: Ten-week mice were orally administered every day for eight consecutive weeks except the mice of normal model groups. The serum levels of anti-ds-DNA antibody IgG, IgM, IFN-gamma Creatinine (Cr), and blood urea nitrogen (BUN) were determined, and 24-hour urine protein was also measured. Renal inflammatory pathology analysis was assessed by hematoxylin-eosin (H&E) staining. The expression of phosphorylated signal transducer and activator of transcription 1 (p-STAT 1) and Janus Kinase 1 (JAK 1) in kidney tissue was determined by direct reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC). Results: The mice treated with Realgar nanoparticle in the high dose-treated (Realgar HD, 0.03 g/kg/d) group exhibited significantly reduced serum levels of anti-dsDNA (p<0.01), IgG (p<0.01), IgM (p<0.01), BUN (p<0.01), Cr (p<0.01), and inflammatory cytokine IFN-gamma (p<0.01) as well as proteinuria (p<0.01) compared to the untreated model MRL/lpr mice. Additionally, high doses of Realgar nanoparticles significantly suppressed the phosphorylations of STAT 1 (p<0.01) and the renal pathological changes. Conclusions: The study indicates that Realgar nanoparticles may be a potential agent to treat LN, and the down-regulated p-STAT1 expression suggests that it may be one of the LN treatment targets for Realgar nanoparticles.